We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Healthpeak Properties Stock Up 13.5% in a Month: Will the Trend Last?
Read MoreHide Full Article
Key Takeaways
DOC stock rallied 13.5% in a month, beating the industry's 2.8% gain amid strong demand for lab assets.
DOC announced about $925M in transactions, reflecting progress in capital allocation and portfolio reshaping.
DOC reported $2.7B liquidity and 86.7% CCRC occupancy in Q3 2025, supporting growth despite competition risks.
Shares of Healthpeak Properties (DOC - Free Report) have rallied 13.5% over the past month, outperforming the industry's upside of 2.8%.
Robust demand for lab assets and an expected rise in senior citizens’ healthcare spending position Healthpeak well to ride on the growth curve. Accretive investments and a solid balance sheet bode well.
In the middle of this month, Healthpeak announced that transaction activity amounted to roughly $925 million, underscoring ongoing progress in its capital allocation strategy.
Image Source: Zacks Investment Research
Factors Behind DOC Stock Price Surge: Will the Trend Last?
Healthpeak’s focus on the lab segment is a strategic fit, and it expects the majority of its future growth to be driven by such assets. This is because the increasing life expectancy of the U.S. population and the growth of biopharma drug development opportunities have promoted the lab real estate market fundamentals. Also, the use of artificial intelligence and machine learning is likely to increase the probability of success in drug research and lower the timeline for development. This is expected to lead to a rise in the allocation of healthcare spending by healthcare research institutes in the coming years.
Going forward, with an expected rise in the senior citizens’ population in the years ahead, DOC’s continuing care retirement community (CCRC) portfolio, which refers to its retirement communities that include independent living, assisted living and skilled nursing units, has a strong upside potential. In the third quarter of 2025, occupancy in its CCRC portfolio was 86.7%.
Healthpeak is making concerted portfolio-repositioning efforts to focus on lab, outpatient medical and CCRC assets. In December 2025 and January 2026, Healthpeak acquired assets worth $600 million. During the fourth quarter of 2025, Healthpeak closed on outpatient medical dispositions totaling about $325 million. Such expansion moves will enable it to benefit from favorable operating trends and tenant demand, driving growth opportunities for the company.
Healthpeak has been taking steps to bolster its near-term liquidity. As of Oct. 23, 2025, the company had available liquidity of around $2.7 billion and a net debt-to-adjusted EBITDAre of 5.3X. Healthpeak had long-term credit ratings of Baa1 (Stable) from Moody’s and BBB+ (Stable) from S&P Global as of Oct. 22, 2025. With investment-grade credit ratings, the company can easily access the debt and equity markets to fund capital commitments at favorable costs.
Analysts seem bullish on this Zacks Rank #3 (Hold) company, with the Zacks Consensus Estimate for its 2025 FFO per share revised upward over the past two months to $1.83. Meanwhile, estimates for 2026 have moved down by 2.1% over the past three months to $1.83.
Key Risks for DOC
Competition from other industry players in the healthcare services sector is a key concern for Healthpeak. Risks associated with rising construction costs and substantial debt burden add to its woes.
The Zacks Consensus Estimate for PLD’s 2025 and 2026 FFO per share is pinned at $5.80 and $6.08, respectively. This calls for year-over-year growth of 4.3% for 2025 and 4.7% for 2026.
The Zacks Consensus Estimate for LAMR’s 2025 and 2026 FFO per share is pegged at $8.19 and $8.83, respectively. This implies year-over-year growth of 2.5% for 2025 and 7.8% for 2026.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Healthpeak Properties Stock Up 13.5% in a Month: Will the Trend Last?
Key Takeaways
Shares of Healthpeak Properties (DOC - Free Report) have rallied 13.5% over the past month, outperforming the industry's upside of 2.8%.
Robust demand for lab assets and an expected rise in senior citizens’ healthcare spending position Healthpeak well to ride on the growth curve. Accretive investments and a solid balance sheet bode well.
In the middle of this month, Healthpeak announced that transaction activity amounted to roughly $925 million, underscoring ongoing progress in its capital allocation strategy.
Image Source: Zacks Investment Research
Factors Behind DOC Stock Price Surge: Will the Trend Last?
Healthpeak’s focus on the lab segment is a strategic fit, and it expects the majority of its future growth to be driven by such assets. This is because the increasing life expectancy of the U.S. population and the growth of biopharma drug development opportunities have promoted the lab real estate market fundamentals. Also, the use of artificial intelligence and machine learning is likely to increase the probability of success in drug research and lower the timeline for development. This is expected to lead to a rise in the allocation of healthcare spending by healthcare research institutes in the coming years.
Going forward, with an expected rise in the senior citizens’ population in the years ahead, DOC’s continuing care retirement community (CCRC) portfolio, which refers to its retirement communities that include independent living, assisted living and skilled nursing units, has a strong upside potential. In the third quarter of 2025, occupancy in its CCRC portfolio was 86.7%.
Healthpeak is making concerted portfolio-repositioning efforts to focus on lab, outpatient medical and CCRC assets. In December 2025 and January 2026, Healthpeak acquired assets worth $600 million. During the fourth quarter of 2025, Healthpeak closed on outpatient medical dispositions totaling about $325 million. Such expansion moves will enable it to benefit from favorable operating trends and tenant demand, driving growth opportunities for the company.
Healthpeak has been taking steps to bolster its near-term liquidity. As of Oct. 23, 2025, the company had available liquidity of around $2.7 billion and a net debt-to-adjusted EBITDAre of 5.3X. Healthpeak had long-term credit ratings of Baa1 (Stable) from Moody’s and BBB+ (Stable) from S&P Global as of Oct. 22, 2025. With investment-grade credit ratings, the company can easily access the debt and equity markets to fund capital commitments at favorable costs.
Analysts seem bullish on this Zacks Rank #3 (Hold) company, with the Zacks Consensus Estimate for its 2025 FFO per share revised upward over the past two months to $1.83. Meanwhile, estimates for 2026 have moved down by 2.1% over the past three months to $1.83.
Key Risks for DOC
Competition from other industry players in the healthcare services sector is a key concern for Healthpeak. Risks associated with rising construction costs and substantial debt burden add to its woes.
Stocks to Consider
Some better-ranked stocks from the broader REIT sector are Prologis Inc. (PLD - Free Report) and Lamar Advertising (LAMR - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for PLD’s 2025 and 2026 FFO per share is pinned at $5.80 and $6.08, respectively. This calls for year-over-year growth of 4.3% for 2025 and 4.7% for 2026.
The Zacks Consensus Estimate for LAMR’s 2025 and 2026 FFO per share is pegged at $8.19 and $8.83, respectively. This implies year-over-year growth of 2.5% for 2025 and 7.8% for 2026.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.